A citation-based method for searching scientific literature

Anthony H Barnett, Ambrish Mithal, Jenny Manassie, Russell Jones, Henning Rattunde, Hans J Woerle, Uli C Broedl. Lancet Diabetes Endocrinol 2014
Times Cited: 345







List of co-cited articles
1076 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Gordon Law, Mehul Desai, David R Matthews. N Engl J Med 2017
73

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
70

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Stephen D Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Michael G Silverman, Thomas A Zelniker, Julia F Kuder, Sabina A Murphy,[...]. N Engl J Med 2019
52

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
Vlado Perkovic, Meg J Jardine, Bruce Neal, Severine Bompoint, Hiddo J L Heerspink, David M Charytan, Robert Edwards, Rajiv Agarwal, George Bakris, Scott Bull,[...]. N Engl J Med 2019
52

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.
Christoph Wanner, Silvio E Inzucchi, John M Lachin, David Fitchett, Maximilian von Eynatten, Michaela Mattheus, Odd Erik Johansen, Hans J Woerle, Uli C Broedl, Bernard Zinman. N Engl J Med 2016
48


SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
Thomas A Zelniker, Stephen D Wiviott, Itamar Raz, Kyungah Im, Erica L Goodrich, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Remo H M Furtado,[...]. Lancet 2019
948
34

Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease.
J-F Yale, G Bakris, B Cariou, J Nieto, E David-Neto, D Yue, E Wajs, K Figueroa, J Jiang, G Law,[...]. Diabetes Obes Metab 2014
157
31


Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus.
David Z I Cherney, Bruce A Perkins, Nima Soleymanlou, Maria Maione, Vesta Lai, Alana Lee, Nora M Fagan, Hans J Woerle, Odd Erik Johansen, Uli C Broedl,[...]. Circulation 2014
702
26

Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease.
J-F Yale, G Bakris, B Cariou, D Yue, E David-Neto, L Xi, K Figueroa, E Wajs, K Usiskin, G Meininger. Diabetes Obes Metab 2013
355
26


Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes.
H J Lambers Heerspink, D de Zeeuw, L Wie, B Leslie, J List. Diabetes Obes Metab 2013
419
25

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
John J V McMurray, Scott D Solomon, Silvio E Inzucchi, Lars Køber, Mikhail N Kosiborod, Felipe A Martinez, Piotr Ponikowski, Marc S Sabatine, Inder S Anand, Jan Bělohlávek,[...]. N Engl J Med 2019
25


Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension.
Ilkka Tikkanen, Kirsi Narko, Cordula Zeller, Alexandra Green, Afshin Salsali, Uli C Broedl, Hans J Woerle. Diabetes Care 2015
271
21

Ertugliflozin in Patients with Stage 3 Chronic Kidney Disease and Type 2 Diabetes Mellitus: The VERTIS RENAL Randomized Study.
George Grunberger, Sarah Camp, Jeremy Johnson, Susan Huyck, Steven G Terra, James P Mancuso, Zhi Wei Jiang, Gregory Golm, Samuel S Engel, Brett Lauring. Diabetes Ther 2018
62
32

Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial.
David Z I Cherney, Bernard Zinman, Silvio E Inzucchi, Audrey Koitka-Weber, Michaela Mattheus, Maximilian von Eynatten, Christoph Wanner. Lancet Diabetes Endocrinol 2017
179
19


Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials.
Vlado Perkovic, Dick de Zeeuw, Kenneth W Mahaffey, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Terrance D Barrett, Michele Weidner-Wells, Hsiaowei Deng, David R Matthews,[...]. Lancet Diabetes Endocrinol 2018
231
19


Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial.
Hans-Ulrich Häring, Ludwig Merker, Elke Seewaldt-Becker, Marc Weimer, Thomas Meinicke, Hans J Woerle, Uli C Broedl. Diabetes Care 2013
258
18

Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial.
Michael Roden, Jianping Weng, Jens Eilbracht, Bruno Delafont, Gabriel Kim, Hans J Woerle, Uli C Broedl. Lancet Diabetes Endocrinol 2013
296
18

Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial.
William T Cefalu, Lawrence A Leiter, Kun-Ho Yoon, Pablo Arias, Leo Niskanen, John Xie, Dainius A Balis, William Canovatchel, Gary Meininger. Lancet 2013
500
18

How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial.
Silvio E Inzucchi, Bernard Zinman, David Fitchett, Christoph Wanner, Ele Ferrannini, Martin Schumacher, Claudia Schmoor, Kristin Ohneberg, Odd Erik Johansen, Jyothis T George,[...]. Diabetes Care 2018
300
18

Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial.
Hans-Ulrich Häring, Ludwig Merker, Elke Seewaldt-Becker, Marc Weimer, Thomas Meinicke, Uli C Broedl, Hans J Woerle. Diabetes Care 2014
251
17

Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study.
Paola Fioretto, Stefano Del Prato, John B Buse, Ronald Goldenberg, Francesco Giorgino, Daniel Reyner, Anna Maria Langkilde, C David Sjöström, Peter Sartipy. Diabetes Obes Metab 2018
58
29

Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial.
Clifford J Bailey, Jorge L Gross, Delphine Hennicken, Nayyar Iqbal, Traci A Mansfield, James F List. BMC Med 2013
200
16

Canagliflozin Slows Progression of Renal Function Decline Independently of Glycemic Effects.
Hiddo J L Heerspink, Mehul Desai, Meg Jardine, Dainius Balis, Gary Meininger, Vlado Perkovic. J Am Soc Nephrol 2017
182
16


Empagliflozin as Add-on Therapy to Pioglitazone With or Without Metformin in Patients With Type 2 Diabetes Mellitus.
Christopher S Kovacs, Veeraswamy Seshiah, Ludwig Merker, Anita Vedel Christiansen, Flavien Roux, Afshin Salsali, Gabriel Kim, Peter Stella, Hans-Juergen Woerle, Uli C Broedl. Clin Ther 2015
60
26

Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin.
J Bolinder, Ö Ljunggren, L Johansson, J Wilding, A M Langkilde, C D Sjöström, J Sugg, S Parikh. Diabetes Obes Metab 2014
280
16

Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin.
David Z I Cherney, Mark E Cooper, Ilkka Tikkanen, Egon Pfarr, Odd Erik Johansen, Hans J Woerle, Uli C Broedl, Søren S Lund. Kidney Int 2018
87
18

The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus.
David Zi Cherney, Bruce A Perkins, Nima Soleymanlou, Ronnie Har, Nora Fagan, Odd Erik Johansen, Hans-Juergen Woerle, Maximilian von Eynatten, Uli C Broedl. Cardiovasc Diabetol 2014
298
16

Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease.
Christoph Wanner, John M Lachin, Silvio E Inzucchi, David Fitchett, Michaela Mattheus, Jyothis George, Hans J Woerle, Uli C Broedl, Maximilian von Eynatten, Bernard Zinman. Circulation 2018
204
15

Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naïve patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trial.
Michael Roden, Ludwig Merker, Anita Vedel Christiansen, Flavien Roux, Afshin Salsali, Gabriel Kim, Peter Stella, Hans J Woerle, Uli C Broedl. Cardiovasc Diabetol 2015
66
22

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Steven P Marso, Stephen C Bain, Agostino Consoli, Freddy G Eliaschewitz, Esteban Jódar, Lawrence A Leiter, Ildiko Lingvay, Julio Rosenstock, Jochen Seufert, Mark L Warren,[...]. N Engl J Med 2016
15

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
Steven P Marso, Gilbert H Daniels, Kirstine Brown-Frandsen, Peter Kristensen, Johannes F E Mann, Michael A Nauck, Steven E Nissen, Stuart Pocock, Neil R Poulter, Lasse S Ravn,[...]. N Engl J Med 2016
15

Empagliflozin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Linagliptin and Metformin: A 24-Week Randomized, Double-Blind, Parallel-Group Trial.
Eirik Søfteland, Juris J Meier, Bente Vangen, Robert Toorawa, Mario Maldonado-Lutomirsky, Uli C Broedl. Diabetes Care 2017
59
25


Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55-80 years with type 2 diabetes.
B Bode, K Stenlöf, S Harris, D Sullivan, A Fung, K Usiskin, G Meininger. Diabetes Obes Metab 2015
142
15

Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial.
J P H Wilding, G Charpentier, P Hollander, G González-Gálvez, C Mathieu, F Vercruysse, K Usiskin, G Law, S Black, W Canovatchel,[...]. Int J Clin Pract 2013
230
15

Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis.
Despoina Vasilakou, Thomas Karagiannis, Eleni Athanasiadou, Maria Mainou, Aris Liakos, Eleni Bekiari, Maria Sarigianni, David R Matthews, Apostolos Tsapas. Ann Intern Med 2013
514
14

Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function.
Brendon L Neuen, Toshiaki Ohkuma, Bruce Neal, David R Matthews, Dick de Zeeuw, Kenneth W Mahaffey, Greg Fulcher, Mehul Desai, Qiang Li, Hsiaowei Deng,[...]. Circulation 2018
118
14

CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis.
Ele Ferrannini, Michael Mark, Eric Mayoux. Diabetes Care 2016
498
14

Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin.
Jan Bolinder, Östen Ljunggren, Joel Kullberg, Lars Johansson, John Wilding, Anna Maria Langkilde, Jennifer Sugg, Shamik Parikh. J Clin Endocrinol Metab 2012
470
14



SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria.
Yukihiro Chino, Yoshishige Samukawa, Soichi Sakai, Yasuhiro Nakai, Jun-ichi Yamaguchi, Takeo Nakanishi, Ikumi Tamai. Biopharm Drug Dispos 2014
152
13

Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial.
Martin Ridderstråle, Knut Robert Andersen, Cordula Zeller, Gabriel Kim, Hans J Woerle, Uli C Broedl. Lancet Diabetes Endocrinol 2014
232
13


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.